Vanitha Sekar

1.8k total citations
33 papers, 1.5k citations indexed

About

Vanitha Sekar is a scholar working on Infectious Diseases, Virology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Vanitha Sekar has authored 33 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Infectious Diseases, 18 papers in Virology and 15 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Vanitha Sekar's work include HIV/AIDS drug development and treatment (28 papers), HIV Research and Treatment (18 papers) and Pharmacological Effects and Toxicity Studies (14 papers). Vanitha Sekar is often cited by papers focused on HIV/AIDS drug development and treatment (28 papers), HIV Research and Treatment (18 papers) and Pharmacological Effects and Toxicity Studies (14 papers). Vanitha Sekar collaborates with scholars based in United States, United Kingdom and Belgium. Vanitha Sekar's co-authors include Richard M. W. Hoetelmans, Éric Lefebvre, Monika Peeters, Martine De Pauw, Goedele De Smedt, Tony Vangeneugden, David Back, Oliver Lenz, Ludo Lavreys and Thomas Berg and has published in prestigious journals such as Gastroenterology, Hepatology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Vanitha Sekar

33 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vanitha Sekar United States 19 954 633 613 537 195 33 1.5k
Beverly Alston United States 13 837 0.9× 796 1.3× 722 1.2× 349 0.6× 527 2.7× 19 1.7k
Bach-Yen Nguyen United States 12 1.6k 1.7× 720 1.1× 793 1.3× 1.1k 2.1× 316 1.6× 13 2.2k
Sonia Rodríguez‐Nóvoa Spain 26 1.5k 1.6× 689 1.1× 549 0.9× 745 1.4× 532 2.7× 72 2.2k
Inmaculada Jiménez‐Nácher Spain 18 759 0.8× 304 0.5× 299 0.5× 461 0.9× 185 0.9× 27 992
Stéphanie Dominguez France 16 590 0.6× 553 0.9× 518 0.8× 370 0.7× 141 0.7× 39 1.1k
Geoffrey J. Yuen United States 22 1.0k 1.1× 416 0.7× 219 0.4× 629 1.2× 123 0.6× 39 1.5k
Dion F. Coakley United States 18 782 0.8× 390 0.6× 176 0.3× 536 1.0× 174 0.9× 25 1.2k
Paola Meraviglia Italy 19 941 1.0× 368 0.6× 111 0.2× 556 1.0× 330 1.7× 61 1.3k
Claudia Martorell United States 14 467 0.5× 598 0.9× 629 1.0× 217 0.4× 155 0.8× 28 1.3k
Andrew Mulato United States 22 1.6k 1.7× 586 0.9× 232 0.4× 1.2k 2.2× 174 0.9× 33 2.1k

Countries citing papers authored by Vanitha Sekar

Since Specialization
Citations

This map shows the geographic impact of Vanitha Sekar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vanitha Sekar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vanitha Sekar more than expected).

Fields of papers citing papers by Vanitha Sekar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vanitha Sekar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vanitha Sekar. The network helps show where Vanitha Sekar may publish in the future.

Co-authorship network of co-authors of Vanitha Sekar

This figure shows the co-authorship network connecting the top 25 collaborators of Vanitha Sekar. A scholar is included among the top collaborators of Vanitha Sekar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vanitha Sekar. Vanitha Sekar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zeuzem, Stefan, Thomas Berg, Edward Gane, et al.. (2013). Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial. Gastroenterology. 146(2). 430–441.e6. 184 indexed citations
2.
Moreno, Christophe, Thomas Berg, Tawesak Tanwandee, et al.. (2012). Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study. Journal of Hepatology. 56(6). 1247–1253. 86 indexed citations
3.
Chokephaibulkit, Kulkanya, Wasana Prasitsuebsai, Orasri Wittawatmongkol, et al.. (2012). Pharmacokinetics of Darunavir/Ritonavir in Asian HIV-1-Infected Children Aged ≥7 Years. Antiviral Therapy. 17(7). 1263–1269. 2 indexed citations
4.
Manns, Michael P., H. W. Reesink, Thomas Berg, et al.. (2011). Rapid Viral Response of Once-Daily Tmc435 plus Pegylated Interferon/Ribavirin in Hepatitis C Genotype-1 Patients: A Randomized Trial. Antiviral Therapy. 16(7). 1021–1033. 57 indexed citations
5.
Sekar, Vanitha, Sabrina Spinosa‐Guzman, Els De Paepe, et al.. (2010). Pharmacokinetics of Multiple-Dose Darunavir in Combination with Low-Dose Ritonavir in Individuals with Mild-to-Moderate Hepatic Impairment. Clinical Pharmacokinetics. 49(5). 343–350. 17 indexed citations
6.
Sekar, Vanitha, Éric Lefebvre, Tine De Marez, et al.. (2010). Pharmacokinetic Interaction between Indinavir and Darunavir with Low-Dose Ritonavir in Healthy Volunteers. Intervirology. 53(3). 176–182. 4 indexed citations
7.
Sekar, Vanitha, Frank Tomaka, Éric Lefebvre, et al.. (2010). Pharmacokinetic Interactions Between Darunavir/Ritonavir and Opioid Maintenance Therapy Using Methadone or Buprenorphine/Naloxone. The Journal of Clinical Pharmacology. 51(2). 271–278. 16 indexed citations
8.
Sekar, Vanitha, Ludo Lavreys, Tom Van de Casteele, et al.. (2010). Pharmacokinetics of Darunavir/Ritonavir and Rifabutin Coadministered in HIV-Negative Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 54(10). 4440–4445. 37 indexed citations
9.
Blanche, Stéphane, Rosa Bologna, Pedro Cahn, et al.. (2009). Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. AIDS. 23(15). 2005–2013. 37 indexed citations
10.
Mills, Anthony, Mark Nelson, Dushyantha Jayaweera, et al.. (2009). Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 23(13). 1679–1688. 199 indexed citations
11.
Sekar, Vanitha, Éric Lefebvre, Martine De Pauw, et al.. (2009). Pharmacokinetic interaction between nevirapine and darunavir with low‐dose ritonavir in HIV‐1‐infected patients. British Journal of Clinical Pharmacology. 68(1). 116–119. 11 indexed citations
12.
Sekar, Vanitha, Éric Lefebvre, Martine De Pauw, Tony Vangeneugden, & Richard M. W. Hoetelmans. (2008). Pharmacokinetics of darunavir/ritonavir and ketoconazole following co‐administration in HIV–healthy volunteers. British Journal of Clinical Pharmacology. 66(2). 215–221. 30 indexed citations
13.
Mathias, Anita, John E. Hinkle, Gong Shen, et al.. (2008). Effect of Ritonavir-Boosted Tipranavir or Darunavir on the Steady-State Pharmacokinetics of Elvitegravir. JAIDS Journal of Acquired Immune Deficiency Syndromes. 49(2). 156–162. 19 indexed citations
14.
Sekar, Vanitha, et al.. (2007). Pharmacokinetic Interaction Between Darunavir and Saquinavir in HIV-negative Volunteers. Therapeutic Drug Monitoring. 29(6). 795–801. 17 indexed citations
15.
Sekar, Vanitha, Sabrina Spinosa‐Guzman, Martine De Pauw, et al.. (2007). The Effect of Different Meal Types on the Pharmacokinetics of Darunavir (TMC114)/Ritonavir in HIV‐Negative Healthy Volunteers. The Journal of Clinical Pharmacology. 47(4). 479–484. 72 indexed citations
16.
Sekar, Vanitha, Éric Lefebvre, Tine De Marez, et al.. (2007). Pharmacokinetics of Darunavir (TMC114) and Atazanavir during Coadministration in HIV-Negative, Healthy Volunteers. Drugs in R&D. 8(4). 241–248. 19 indexed citations
17.
Sekar, Vanitha. (2006). Pharmacokinetic Interaction Between TMC114 and Ketoconazole, in the Absence and Presence of Low-Dose Ritonavir. 3 indexed citations
18.
Sekar, Vanitha. (2006). Pharmacokinetic Interaction Between the HIV Protease Inhibitors TMC114 and Saquinavir, in the Presence of Low-Dose Ritonavir. 5 indexed citations
19.
Sekar, Vanitha. (2006). Pharmacokinetic Interaction Between the Antiretroviral Agents TMC114 and Nevirapine, in the Presence of Low-Dose Ritonavir. 6 indexed citations
20.
Gobburu, Jogarao & Vanitha Sekar. (2002). Application of modeling and simulation to integrate clinical pharmacology knowledge across a new drug application. International Journal of Clinical Pharmacology and Therapeutics. 40(7). 281–288. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Beverly Alston Breakdown of academic impact, for papers by Bach-Yen Nguyen Breakdown of academic impact, for papers by Sonia Rodríguez‐Nóvoa Breakdown of academic impact, for papers by Inmaculada Jiménez‐Nácher Breakdown of academic impact, for papers by Stéphanie Dominguez Breakdown of academic impact, for papers by Geoffrey J. Yuen Breakdown of academic impact, for papers by Dion F. Coakley Breakdown of academic impact, for papers by Paola Meraviglia Breakdown of academic impact, for papers by Claudia Martorell Breakdown of academic impact, for papers by Andrew Mulato
Rankless by CCL
2026